<DOC>
	<DOCNO>NCT00142987</DOCNO>
	<brief_summary>Recent literature demonstrate group IBS sufferer experience mixed bowel habit may similar IBS-C patient IBS-D patient . This study evaluate efficacy safety tegaserod 6 mg b.i.d . woman IBS mixed bowel habit , exclude predominant diarrhea .</brief_summary>
	<brief_title>Efficacy Tegaserod Relieving Symptoms Female Patients With Irritable Bowel Syndrome ( IBS ) , Excluding Those With Predominant Diarrhea IBS</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>woman , outpatient , 1865 year age IBSC IBS mixed bowel habit In 12 month precede study entry , least 12 week ( necessarily consecutive ) abdominal discomfort/pain 2 3 feature : 1 ) relieve defecation ; 2 ) onset associate change stool frequency ; 3 ) onset associate change form ( appearance ) stool . Had fulfill follow criterion ( IBS questionnaire ) last 3 month prior study entry : abdominal discomfort pain present least 3 week last 3 month , least two follow : abdominal discomfort pain get good stop bowel movement ; change bowel movement frequency abdominal discomfort pain start ; change bowel movement consistency abdominal discomfort pain start IBSD report constipation diarrhea criterion evidence structural abnormality gastrointestinal tract diseases/conditions affect bowel transit history bowel obstruction , symptomatic gallbladder disease , suspect sphincter Oddi dysfunction , abdominal adhesion evidence cathartic colon history laxative abuse Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Tegaserod , IBS-C , woman , mixed bowel habit</keyword>
</DOC>